Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash from Financing Activities (2019 - 2024)

Goldenwell Biotech (GWLL) has disclosed Cash from Financing Activities for 5 consecutive years, with $70000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash from Financing Activities rose 15.92% year-over-year to $70000.0, compared with a TTM value of $117150.0 through Jun 2025, down 31.79%, and an annual FY2024 reading of $119250.0, down 0.95% over the prior year.
  • Cash from Financing Activities was $70000.0 for Q4 2024 at Goldenwell Biotech, up from -$2100.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $170125.0 in Q1 2021 and bottomed at -$2100.0 in Q3 2024.
  • Average Cash from Financing Activities over 4 years is $65692.8, with a median of $54625.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities soared 2230.48% in 2021, then crashed 103.5% in 2024.
  • Year by year, Cash from Financing Activities stood at $1000.0 in 2020, then skyrocketed by 16912.5% to $170125.0 in 2021, then tumbled by 64.5% to $60388.0 in 2023, then rose by 15.92% to $70000.0 in 2024.
  • Business Quant data shows Cash from Financing Activities for GWLL at $70000.0 in Q4 2024, -$2100.0 in Q3 2024, and $49250.0 in Q2 2024.